In the US, Mobius Therapeutics has recalled two lots of Mitosol (mitomycin for solution) 0.2 mg/vial Kit for Opthalmic Use,

In the US, Mobius Therapeutics has recalled two lots of Mitosol (mitomycin for solution) 0.2 mg/vial Kit for Opthalmic Use, after the lots were found to be potentially contaminated with a strain of yeast. The Mitomisol 0.2 mg/vial Kit for Opthalmic Use is an antimetabolite indicated, as an adjunct, during ab externo glaucoma surgery. Mobius Therapeutics suggests that the affected lots should be considered non-sterile and unsafe. It warns that use of the potentially contaminated products could result in serious eye infections and possible blindness; however, the company has not yet received any reports of adverse events related to this recall.